Skip to main content

Life Tech Licensing PCR IP from Roche for Diagnostic Applications

NEW YORK (GenomeWeb News) – Roche and Life Technologies today announced two licensing deals granting Life Tech access to PCR technologies.

Roche is granting Life Tech an in vitro diagnostic product license to all of its PCR patents for real-time PCR and other PCR-related technology in the diagnostic field. The agreements also cover reagents and methods for using SYBR Green I technology, melting curve analysis for real-time PCR, and the rights to use high-resolution melting curve analysis technology in the diagnostics field, the two firms said.

Financial terms of the deals were not disclosed.

Roche has licensed the IP portfolio in cooperation with Idaho Technology, it said. The two firms forged a licensing deal in 2005 granting Idaho Tech access to Roche's PCR patents.

Other companies that Roche has licensed its PCR IP portfolio to, in cooperation with Idaho Tech, include Qiagen, Thermo Fisher Scientific, and Takara Bio.

Paul Brown, head of Roche Molecular Diagnostics, said in a statement, "Roche has a broad, active out-licensing program for its PCR-based intellectual property portfolio. By continuing to out-license this technology, we contribute to the development of well-validated techniques within the diagnostics field."

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.